162 related articles for article (PubMed ID: 27124410)
21. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Lee EK; Wong WW; Trudeau ME; Chan KK
Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.
Martín-Jiménez M; Rodríguez-Lescure A; Ruiz-Borrego M; Seguí-Palmer MA; Brosa-Riestra M
Clin Transl Oncol; 2009 Jan; 11(1):41-7. PubMed ID: 19155203
[TBL] [Abstract][Full Text] [Related]
24. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.
Clarke CS; Hunter RM; Shemilt I; Serra-Sastre V
PLoS One; 2017; 12(3):e0172731. PubMed ID: 28248984
[TBL] [Abstract][Full Text] [Related]
25. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
Verbeek JGE; Atema V; Mewes JC; van Leeuwen M; Oldenburg HSA; van Beurden M; Hunter MS; van Harten WH; Aaronson NK; Retèl VP
Breast Cancer Res Treat; 2019 Dec; 178(3):573-585. PubMed ID: 31451978
[TBL] [Abstract][Full Text] [Related]
29. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
32. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Analysis of MammaPrint
Luyendijk M; Jager A; Buijs SM; Siesling S; Groot CAU; Blommestein HM
Pharmacoeconomics; 2023 Aug; 41(8):981-997. PubMed ID: 37245167
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
35. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
38. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
